Published in Mod Pathol on May 03, 2013
Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int (2015) 0.83
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res (2016) 0.78
The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes (Basel) (2016) 0.75
Hepatocellular carcinoma. Lancet (2012) 18.09
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A (2010) 4.73
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet (2010) 4.26
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci U S A (2003) 3.52
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett (2010) 1.64
Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol (2007) 1.53
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res (2006) 1.05
Fibrolamellar carcinomas are positive for CD68. Mod Pathol (2010) 1.03
Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol (2010) 0.94
Fighting the bushfire in HCC trials. J Hepatol (2011) 0.84
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol (2011) 3.03
A prospective evaluation of a protocol for magnetic resonance imaging of patients with implanted cardiac devices. Ann Intern Med (2011) 2.81
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet (2012) 2.63
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis (2007) 2.42
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res (2006) 2.35
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol (2007) 2.28
Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol (2003) 2.20
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology (2002) 2.13
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res (2002) 2.00
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer (2013) 1.94
Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet (2015) 1.94
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis (2005) 1.91
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology (2010) 1.86
Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med (2008) 1.82
Practice patterns in cervical cancer screening and human papillomavirus testing. Am J Clin Pathol (2012) 1.81
Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol (2013) 1.77
Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc (2006) 1.74
Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol (2002) 1.74
Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol (2005) 1.66
Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology (2013) 1.66
Assessment of hepatic steatosis by transplant surgeon and expert pathologist: a prospective, double-blind evaluation of 201 donor livers. Liver Transpl (2013) 1.62
Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J (2009) 1.62
Role for hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest (2005) 1.62
TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol (2009) 1.61
Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol (2013) 1.58
Chronic intermittent hypoxia predisposes to liver injury. Hepatology (2007) 1.57
Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem (2004) 1.56
ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 1.54
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics (2008) 1.53
Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment. AJR Am J Roentgenol (2009) 1.52
Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology (2002) 1.51
Telomere length as a risk factor for hereditary prostate cancer. Prostate (2013) 1.50
Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. Ann Surg Oncol (2012) 1.50
Chronic intermittent hypoxia and acetaminophen induce synergistic liver injury in mice. Exp Physiol (2008) 1.48
Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl (2004) 1.47
Telomeres: prognostic markers for solid tumors. Int J Cancer (2006) 1.44
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biol Ther (2011) 1.44
ACR Appropriateness Criteria® acute pancreatitis. Ultrasound Q (2014) 1.44
Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. Am J Surg Pathol (2013) 1.42
Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull (2009) 1.32
Eosinophilic pancreatitis and increased eosinophils in the pancreas. Am J Surg Pathol (2003) 1.31
Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology (2003) 1.29
Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging (2012) 1.28
Delayed enhancement MR imaging: utility in myocardial assessment. Radiographics (2006) 1.28
Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat (2006) 1.27
Human prostate cancer precursors and pathobiology. Urology (2003) 1.27
Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. Radiographics (2011) 1.26
Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol (2004) 1.26
Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol (2002) 1.25
Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl (2007) 1.22
Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res (2011) 1.21
Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol (2005) 1.21
Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol (2006) 1.19
Living donor liver transplantation in adults: vascular variants important in surgical planning for donors and recipients. AJR Am J Roentgenol (2003) 1.17
Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol (2005) 1.16
Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol (2013) 1.15
Treatment of chronic hepatitis C: a systematic review. Hepatology (2002) 1.14
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol (2011) 1.14
Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology (2014) 1.14
Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. Hum Immunol (2006) 1.14
Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology (2011) 1.13
Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res (2013) 1.13
Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol (2007) 1.13
Malignant transformation of hepatic adenomas. Mod Pathol (2008) 1.13
Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol (2008) 1.13
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther (2010) 1.12
A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A (2012) 1.12
Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg (2011) 1.11
Brief report: a bioassay to identify primary human prostate cancer repopulating cells. Stem Cells (2011) 1.11
Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol (2012) 1.11